Within a week of the executive order, software that was "AI-powered" will be "SI-powered". The product will be identical. Some of it will be the same chatbot bolted onto the same document system that was being sold as AI last month.
We wrote about AI washing when the first wave arrived. The new label makes the same test necessary again, with one addition: a vendor now has a fresh word to imply capability it cannot demonstrate.
Why the word is doing no work
The order defines Super Intelligence as the technologies already covered by artificial intelligence under existing US statute. Same scope, new name. So "we now offer SI" conveys precisely nothing that "we offer AI" did not.
Watch for the sleight of hand. In the safety literature, superintelligence means a system exceeding human performance across essentially all domains — a hypothetical, and nothing on the market today. A vendor using the federal term while implying the academic one is trading on an ambiguity created last week. See what SI actually means.
The questions that cut through it
"What changed in the product when the name changed?" If the answer is a slide deck, you have your answer.
"Show me the same input ten times." Reproducibility is a property you can watch in a demo. No amount of renaming affects it.
"For a given output, what can my reviewer see about how it was produced?" Source citation, confidence, the version that produced it, a tamper-evident record. Or nothing.
"How am I told when the model changes, and can I stay on the old one?" The question that decides whether your validated state survives contact with the vendor's release schedule.
"Which requirements does your evidence cover, and which remain mine?" Any vendor answering "all of them" is describing something that cannot exist.
The full version is in qualifying an AI vendor, and it is unchanged, because the questions were never about the label.
What to do with your own language
There is a temptation to rebrand your own materials to SI, on the grounds that it sounds current. Two reasons not to.
First, your buyers are quality and validation professionals, and the ones worth having will recognise a relabel. In an industry that runs on trust, being the company that did not redraw its slides the week the word changed is worth more than being early.
Second, every standard you are audited against still says artificial intelligence. Your documentation should match the regulations, not the news cycle — see US says SI, Europe says AI.
If you are evaluating tools right now, the framework in how to evaluate GxP software works exactly as before, and GxP software covers the wider landscape.
Where to go next
Explore GxP Copilot for AI-native validation, TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.
